Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo.
about
Coordinate enhancement of transgene transcription and translation in a lentiviral vectorDelivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor ageStriatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.Gene transfer into rat brain using adenoviral vectors.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersNeuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease.Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses.Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression.Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.Gene therapy progress and prospects: adenoviral vectors.Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.Versatility of gene therapy vectors through viruses.Regulatable gene expression systems for gene therapy applications: progress and future challenges.Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialViral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.Gene therapy to enhance allograft incorporation after host tissue irradiationRegulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators.Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivo.Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.Molecular neurosurgery: vectors and vector delivery strategies.pUNISHER: a high-level expression cassette for use with recombinant viral vectors for rapid and long term in vivo neuronal expression in the CNS.Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression.Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination.The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transferEffects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model.Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression.Adenovirus-mediated CTLA4Ig or CD40Ig gene transfer delays pancreatic islet rejection in a rat-to-mouse xenotransplantation model after systemic but not local expression.Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area.Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
P2860
Q25255153-61A25CF1-8EDC-402E-8741-A6E55D97A82CQ33228402-B5BFA99D-5894-48A5-B097-C75D4C944DAEQ33713348-2DAE99F4-5F07-4F84-ADC9-B17E4F3B044DQ33828114-96C3F01B-FC8A-4619-B2F8-907AC217AC8CQ33904294-CB50367C-ECDF-4841-8A3D-E2EB73512F26Q33985663-1BD5EE25-1953-4D94-A705-D76F9E1DA641Q34074765-49151CA9-1B62-40E6-890D-2C21166E3786Q34233124-E51B905A-F8EF-4665-8358-916DADBFE483Q34546483-0D9C1AB4-5217-4F09-8570-57865B6B5530Q35069550-ECA3B708-F9F0-4B1C-92F3-59B78B1AC2F9Q35118919-20B171EE-0A11-4653-BEA0-C69B2A1F8D82Q35165719-1077CA80-1D5B-4219-9875-AC07406C35D5Q35870480-2075C8A9-363E-411E-907B-3E0EC56D67CFQ36150489-0C93361F-DAEF-4432-A6C2-ED9596DF7B3EQ36157542-1D379F95-AF28-4A42-92F6-5BAB5D7BD6CDQ36200438-D02BBB91-4000-4B12-9B43-29B8450A824AQ36274402-E52CF8E8-7682-45DC-A21A-3922798A440FQ36498762-95F8C43F-0D85-4772-B61E-1BDBD4288C1AQ36534329-78263D7D-1324-4D0E-A63F-B585A6E08BEDQ36960666-37D0E57B-7AB1-4187-8563-635AEF95D074Q36975928-0EF74638-685E-4957-885B-BB18DDE06A19Q37079181-6CC234BB-5855-45D7-BEA0-4934C8BD7A61Q37099841-BCE375DB-86FF-4115-BA50-5F2DF395E94EQ37403279-D5B7DDBE-259B-4D36-9014-3A68C794FF8AQ37998570-2B857601-B993-419E-8C20-43FEF21271E7Q38461882-8BA7EDA6-3930-4403-B922-853BDF0C1906Q38761724-6372C14C-D8B7-4DB2-9EF7-DDD9E93001A8Q40606300-2B73D753-A7CA-4847-9A66-D52AB37D3A1CQ40802046-A8FBC797-F557-4829-9EAD-007361B894AAQ41189810-9BD37524-1AB8-4240-B505-50A9B1C057EFQ42144457-968D9071-E697-4D3F-84DA-0567F979D064Q42220418-75854A96-189A-4021-BA5C-965BEAA50943Q42613158-F4E120A4-4C51-43BD-AD61-23244D30A4BCQ43935181-426C69B5-97ED-4169-BE7C-B1EA100A0E91Q45858691-FFB59549-5732-4C8D-80A3-8490E8CC37BFQ47318878-EE652589-53D3-4F19-9031-B58DC0B29DBF
P2860
Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Strong promoters are the key t ...... livery into the brain in vivo.
@en
Strong promoters are the key t ...... livery into the brain in vivo.
@nl
type
label
Strong promoters are the key t ...... livery into the brain in vivo.
@en
Strong promoters are the key t ...... livery into the brain in vivo.
@nl
prefLabel
Strong promoters are the key t ...... livery into the brain in vivo.
@en
Strong promoters are the key t ...... livery into the brain in vivo.
@nl
P356
P1433
P1476
Strong promoters are the key t ...... livery into the brain in vivo.
@en
P2093
Löwenstein PR
P304
P356
10.1006/MTHE.2000.0140
P577
2000-10-01T00:00:00Z